Literature DB >> 15870181

Haploinsufficiency, rather than the effect of an excessive production of soluble CD95 (CD95{Delta}TM), is the basis for ALPS Ia in a family with duplicated 3' splice site AG in CD95 intron 5 on one allele.

Joachim Roesler1, Jose-Maria Izquierdo, Martin Ryser, Angela Rösen-Wolff, Manfred Gahr, Juan Valcarcel, Michael J Lenardo, Lixin Zheng.   

Abstract

Autoimmune lymphoproliferative syndrome type Ia (ALPS Ia) is caused by mutations in the CD95/APO1/FAS (TN-FRSF6) gene, which lead to a defective CD95 ligand (CD95L)-induced apoptosis. Soluble CD95 (sCD95) has been suggested to play an important role in the pathogenesis of diverse autoimmune and malignant diseases by antagonizing CD95L. Here we evaluate a family with 4 of its 5 members harboring an ex-6-3C-->G mutation that affects the splice cis regulatory region (cctacag/ex-6-->cctagag/ex-6) of the CD95 gene. The mutation causes skipping of exon-6, which encodes the transmembrane region of CD95, and thereby leads to an excessive production of sCD95 in all 4 affected individuals. The mutation is associated with a low penetrance of disease phenotype and caused mild and transient ALPS in one male patient whereas all other family members are completely healthy. In all family members with the mutation we found that the cell surface expression of CD95 was low and the activated T cells were resistant to CD95-induced apoptosis. Unexpectedly, excessive production or addition of sCD95 had no effect on the CD95-induced apoptosis in diverse cells. In contrast, increasing the surface expression of CD95 was able to correct the defect in apoptosis. Thus we conclude that the ALPS in the one male patient was caused by haploinsufficiency of membrane CD95 expression. Our data challenge the hypothesis that sCD95 causes autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15870181     DOI: 10.1182/blood-2004-08-3104

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

1.  Onset of autoimmune lymphoproliferative syndrome (ALPS) in humans as a consequence of genetic defect accumulation.

Authors:  Aude Magerus-Chatinet; Bénédicte Neven; Marie-Claude Stolzenberg; Cécile Daussy; Peter D Arkwright; Nina Lanzarotti; Catherine Schaffner; Sophie Cluet-Dennetiere; Filomeen Haerynck; Gérard Michel; Christine Bole-Feysot; Mohammed Zarhrate; Isabelle Radford-Weiss; Serge P Romana; Capucine Picard; Alain Fischer; Frédéric Rieux-Laucat
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

2.  FAS haploinsufficiency is a common disease mechanism in the human autoimmune lymphoproliferative syndrome.

Authors:  Hye Sun Kuehn; Iusta Caminha; Julie E Niemela; V Koneti Rao; Joie Davis; Thomas A Fleisher; João B Oliveira
Journal:  J Immunol       Date:  2011-04-13       Impact factor: 5.422

3.  Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome.

Authors:  Kennichi C Dowdell; Julie E Niemela; Susan Price; Joie Davis; Ronald L Hornung; João Bosco Oliveira; Jennifer M Puck; Elaine S Jaffe; Stefania Pittaluga; Jeffrey I Cohen; Thomas A Fleisher; V Koneti Rao
Journal:  Blood       Date:  2010-04-01       Impact factor: 22.113

4.  Strict 3' splice site sequence requirements for U2 snRNP recruitment after U2AF binding underlie a genetic defect leading to autoimmune disease.

Authors:  Anna Corrionero; Veronica A Raker; José María Izquierdo; Juan Valcárcel
Journal:  RNA       Date:  2011-01-13       Impact factor: 4.942

5.  Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations.

Authors:  Susan Price; Pamela A Shaw; Amy Seitz; Gyan Joshi; Joie Davis; Julie E Niemela; Katie Perkins; Ronald L Hornung; Les Folio; Philip S Rosenberg; Jennifer M Puck; Amy P Hsu; Bernice Lo; Stefania Pittaluga; Elaine S Jaffe; Thomas A Fleisher; V Koneti Rao; Michael J Lenardo
Journal:  Blood       Date:  2014-01-07       Impact factor: 22.113

6.  A missense mutation in the extracellular domain of Fas: the most common change in Argentinean patients with autoimmune lymphoproliferative syndrome represents a founder effect.

Authors:  María Gabriela Simesen de Bielke; Judith Yancoski; Carlos Rocco; Laura E Pérez; Claudio Cantisano; Néstor Pérez; Matías Oleastro; Silvia Danielian
Journal:  J Clin Immunol       Date:  2012-07-03       Impact factor: 8.317

Review 7.  Genetic defects of apoptosis and primary immunodeficiency.

Authors:  Helen C Su; Michael J Lenardo
Journal:  Immunol Allergy Clin North Am       Date:  2008-05       Impact factor: 3.479

8.  FAS Haploinsufficiency Caused by Extracellular Missense Mutations Underlying Autoimmune Lymphoproliferative Syndrome.

Authors:  María Gabriela Simesen de Bielke; Laura Perez; Judith Yancoski; João Bosco Oliveira; Silvia Danielian
Journal:  J Clin Immunol       Date:  2015-11-12       Impact factor: 8.317

Review 9.  The three as: Alternative splicing, alternative polyadenylation and their impact on apoptosis in immune function.

Authors:  Davia Blake; Kristen W Lynch
Journal:  Immunol Rev       Date:  2021-08-08       Impact factor: 12.988

10.  Functional Consequences for Apoptosis by Transcription Elongation Regulator 1 (TCERG1)-Mediated Bcl-x and Fas/CD95 Alternative Splicing.

Authors:  Marta Montes; Mayte Coiras; Soraya Becerra; Cristina Moreno-Castro; Elena Mateos; Jara Majuelos; F Javier Oliver; Cristina Hernández-Munain; José Alcamí; Carlos Suñé
Journal:  PLoS One       Date:  2015-10-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.